979 results match your criteria: "Imaging in Restrictive Cardiomyopathy"
Open Heart
December 2024
Cedars-Sinai Medical Center, Los Angeles, California, USA
Background: Cardiac amyloidosis (CA) is an underdiagnosed, progressive and lethal disease. Machine learning applied to common measurements derived from routine echocardiogram studies can inform suspicion of CA.
Objectives: Our objectives were to test a random forest (RF) model in detecting CA.
JACC Case Rep
November 2024
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Rheumatic heart disease (RHD) and endomyocardial fibrosis (EMF) are major causes of cardiac disease in low-income countries. We present a case of a patient with mitral stenosis and restrictive cardiomyopathy, initially attributed to severe RHD, but with disease progression despite valve replacement, likely secondary to previously undiagnosed EMF.
View Article and Find Full Text PDFHeart Views
October 2024
Department of Cardiology, Royal Lancaster Infirmary, Lancaster, United Kingdom.
Arq Bras Cardiol
October 2024
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.
Ann Pediatr Cardiol
October 2024
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
Partial cavopulmonary shunt is an established procedure for patients with abnormal right ventricular (RV) physiology. Late failure of the Glenn shunt is usually due to further progression of the primary disease process. However, there may be surprises, as in our patient.
View Article and Find Full Text PDFCurr Probl Cardiol
January 2025
Lung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int J Cardiol Heart Vasc
December 2024
Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
BMJ Case Rep
November 2024
Department of Cardiology, Centro Hospitalar de Setubal EPE, Setubal, Portugal.
BMJ Case Rep
October 2024
School of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Curr Probl Cardiol
January 2025
Instituto do Coração (InCor), Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
Kardiol Pol
November 2024
Department of Heart Failure and Transplantology, National Institute of Cardiology, Warszawa, Poland.
BMC Cardiovasc Disord
October 2024
Department of Cardiology, Songshan General Hospital, 69 Xingguang Street, Chongqing, 401120, China.
Int J Cardiol
January 2025
Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Italy.
Over the last 20 years, the scientific progresses in molecular biology and genetics in combination with the increasing use in the clinical setting of contrast-enhanced cardiac magnetic resonance (CMR) for morpho-functional imaging and structural myocardial tissue characterization have provided important new insights into our understanding of the distinctive aspects of cardiomyopathy, regarding both the genetic and biologic background and the clinical phenotypic features. This has led to the need of an appropriate revision and upgrading of current nosographic framework and pathobiological categorization of heart muscle disorders. This article proposes a new definition and classification of cardiomyopathies that rely on the combination of the distinctive pathobiological basis (genetics, molecular biology and pathology) and the clinical phenotypic pattern (morpho-functional and structural features), leading to the proposal of three different disease categories, each of either genetic or non-genetic etiology and characterized by a combined designation based on both "anatomic" and "functional" features, i.
View Article and Find Full Text PDFCurr Probl Cardiol
December 2024
Department of Cardiovascular Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Zhonghua Xin Xue Guan Bing Za Zhi
September 2024
Department of Magnetic Resonance Imaging, Fuwai Hospital, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Cureus
July 2024
First Department of Internal Medicine, Athens Medical Group, Athens, GRC.
Cardiac amyloidosis is a rare but increasingly recognized condition characterized by the deposition of amyloid fibrils in cardiac tissue, leading to structural and functional heart impairment. This infiltrative cardiomyopathy often mimics more common cardiac conditions, posing significant diagnostic challenges. Particularly deceptive is its presentation as non-ST-segment elevation myocardial infarction (NSTEMI), where the clinical overlap necessitates considering amyloidosis in differential diagnoses.
View Article and Find Full Text PDFLancet Oncol
August 2024
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology & Laboratory Medicine, Cleveland Clinic Florida, Weston, FL, USA.
Rev Cardiovasc Med
February 2024
Division of Non-Invasive Cardiology, Department of Medicine, University of Szeged, 6720 Szeged, Hungary.
J Clin Med
July 2024
Department of Medicine, Alpert Medical School of Brown University, Providence, RI 02903, USA.
Cureus
June 2024
Department of Cardiovascular Medicine, University of Utah, Salt Lake City, USA.
Cardiac amyloidosis is an infiltrative disease characterized by the extracellular deposition of misfolded protein in the myocardium, leading to increased stiffness and an eventual restrictive cardiomyopathy. The slow onset of symptoms and overlap with other cardiomyopathies make prompt diagnosis a challenge. Clinicians should be alerted and include amyloidosis in their differential diagnosis, particularly in patients with heart failure with preserved ejection fraction, unexplained left ventricle hypertrophy, particularly in those shown intolerance to previous antihypertensive medication, and early orthopedic manifestations of the disease such as carpal tunnel syndrome and spinal stenosis.
View Article and Find Full Text PDFCurr Opin Cardiol
September 2024
Houston Methodist Debakey Heart & Vascular Center, Houston, Texas, USA.
Purpose Of Review: Cardiac amyloidosis is a condition marked by the misfolding of precursor proteins into insoluble amyloid fibrils, leading to restrictive cardiomyopathy and heart failure symptoms. This review discusses advancements in nuclear imaging techniques that enhance the diagnosis and guide the management of cardiac amyloidosis, addressing the critical need for early and accurate detection in clinical practice.
Recent Findings: Recent studies and guidelines emphasizes the pivotal role of nuclear imaging techniques in diagnosing cardiac amyloidosis.
Cureus
June 2024
Department of Cardiology, "Heratsi" Hospital Complex № 1, Yerevan, ARM.
Left ventricular thrombus (LVT) has historically been reported as a complication of acute left ventricular (LV) myocardial infarction. It is most commonly observed in cases of LV systolic dysfunction attributed to ischemic or nonischemic etiologies. Conversely, the occurrence of LVT in normal LV systolic function is an exceptionally rare presentation and is predominantly associated with conditions such as hypereosinophilic syndrome (HES), cardiac amyloidosis, left ventricular noncompaction, hypertrophic cardiomyopathy (HCM), hypercoagulability states, immune-mediated disorders, and malignancies.
View Article and Find Full Text PDFSemin Nucl Med
September 2024
Division of Nuclear Medicine, Department of Radiology, Brigham and Women's Hospital, Boston, MA; Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; CV Imaging Program, Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital, Boston, MA. Electronic address:
Cardiac amyloidosis (CA) is caused by the misfolding, accumulation and aggregation of proteins into large fibrils in the extracellular compartment of the myocardium, leading to restrictive cardiomyopathy, heart failure and death. The major forms are transthyretin (ATTR) CA and light-chain (AL) CA, based on the respective precursor protein. Each of them requires early diagnosis for a timely treatment initiation that will improve patient outcomes.
View Article and Find Full Text PDF